UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF

Sex: All

Ages: 18 Years – 89 Years

Healthy volunteers: No

Phase: NA

Enrollment: 10

Sponsor: David Lanfear

Summary

This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.

Eligibility Criteria

Inclusion Criteria: * Age 18-89 years * Ejection Fraction (EF) \>40% and =\35 ng/L or NTproBNP \>125 ng/L at any time * Expected ability to fully participate in study (can tolerate study processes, no long travel) Exclusion Criteria: * Unable to provide informed consent * Previous documented EF =\< 35% * Currently on BB =\>25% target dose * Uncontrolled hypertension (systolic BP \> 180 at enrollment) * Has contraindications to all BB or intolerance to metoprolol * Systolic BP \< 100 or heart rate \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07054489). StuddyBuddy aggregates publicly available trial information.